CD34+ Cells Uses, Dosage, Side Effects and more
CD34+ Cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).
| Trade Name | CD34+ Cells |
| Generic | Autologous peripheral blood-derived CD34+ cells |
| Autologous peripheral blood-derived CD34+ cells Other Names | CD34+ Cells, CLBS119 |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How CD34+ Cells works
CD34+ Cells have potential tissue repair ability in part due to its anti-inflammatory function which were demonstrated in pre-clinical models, including one of lung inflammation. Due to the pre-programmed tissue repair effects mediated by anti-inflammatory and pro-angiogenic functions of these cells, this cell therapy is currently being investigated against COVID-19-induced lung damage in recovered adult patients that still are experiencing hypoxia and require supplemental oxygen.
